Skip to main content

Advertisement

SpringerLink
Log in

How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol

  • Correspondence
  • Published:
Rheumatology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P et al (2014) Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis 73:2094–2100

    Article  CAS  PubMed  Google Scholar 

  2. Keystone E, Heijde D, Mason D Jr, Landewe´ R, Vollenhoven RV, Combe B et al (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58:3319–3329

    Article  CAS  PubMed  Google Scholar 

  3. Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C (2007) Physicians of the Swiss clinical quality management program for rheumatoid arthritis. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 57:679–685

    Article  PubMed  Google Scholar 

  4. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1316–1322

    Article  Google Scholar 

  5. Murota A, Kaneko Y, Yamaoka K, Takeuchi T (2016) Safety of biologic agents in elderly patients with rheumatoid arthritis. J Rheumatol 43:1984–1988

    Article  CAS  Google Scholar 

  6. Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L (2018) Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice. Clin Exp Rheumatol 36:29–35

    Google Scholar 

  7. Tornero Molina J, Sanmartí Sala R, Rodríguez Valverde V, Martín Mola E, Marenco de la Fuente JL, González Álvaro I, Muñoz Fernández S, Gómez-Reino Carnota J, Carreño Pérez L, Batlle Gualda E, Balsa Criado A, Andreu JL, Alvaro-Gracia JM, Martínez López JA, Loza Santamaría E (2010) Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatol Clin 6:23–36

    Article  PubMed  Google Scholar 

  8. Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA, Tavernier C, Maillefert JF (2005) Survival and safety of treatment with infliximab in the elderly population. Rheumatology 44:695–696

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

RENACER Study Group (REgistro NAcional CERtolizumab): José Antonio González Ferrández, Carmen Moragues Pastor, Ana Urruticoechea Arana, José Rey Rey, Raúl Veiga Cabello, Ángel Aragón Díez, Noelia Vázquez Fuentes, Anna Martínez Cristóbal, Mª del Pilar Navarro Alonso, Sergi Ordoñez Palau, Alejandro Muñoz Jiménez, José Miguel Ruiz Martín, Asuncion Acosta Pereira, Ángel María García Aparicio, Jesús Carlos Fernández, Mercedes Morcillo, Emilio Giner Serret, Nuria Montala Palau, Carlos Rodríguez Escalera, José Campos Esteban, Juan José de Agustín de Oro, Pedro Giralt Celiméndiz, Desireé Ruiz Vílchez, Silvia Paredes González-Albo, Laura Garrido Courel, Carmen Olga Sánchez González, Maria del Pilar Ahijado Guzmán, Patricia Castro Pérez, Rosa Garcia Portales, Julia Fernández Melón, Gabriel Mercadal Orfila, José Raúl Noguera Pons, Concepción Moll Tuduri, Mª Dolores García Armario, Víctor Eliseo Quevedo Vila, Juan José Lerma Garrido, Antonio Gracia Pérez, Elena Aurrecoechea Aguinaga, Amalia Rueda Cid, Marina Soledad Moreno García, Eduardo Loza Cortina, Delia Taverner Torrent, Rebeca Belmonte Gómez, María Jesús Martínez Blasco, Raúl Moreno Domínguez, Jenaro Graña Gil, Raúl Cortés Verdú, Mª Teresa Ruiz Jimeno, Cristina Mata Arnaiz, Georgina Salvador Alarcón, Ana María Fernández Ortiz, Marco Moreno Zazo, Susana Barona Trapote, Manuel Utrilla Utrilla, Jaime Calvo Alén, César Antonio Egües Dubuc, Azucena Hernández Sanz, Mar López-Sidro Ibáñez, César Díaz Torne, Vicente Aldasoro Cáceres, Vera Ortiz Santamaría, Mª Ángeles Hernández del Río, Leticia del Olmo Pérez, Jesús Quijada Carrera, Claudia Stoye, Mª de los Ángeles Belmonte, Mª Ángeles Acosta Mérida, Carlos Tomás Roura, Arantxa Conesa Mateos, Joan Dalmau Carolà and José María Salazar Vallinas.

Funding

This study have not received any funding.

Author information

Authors and Affiliations

  1. Rheumatology Department, Hospital General Hospitalet-Sant Joan Despí Moisès Broggi, C/Avinguda Josep Molins 29-41, 08906, Hospitalet Llobregat, Catalunya, Spain

    Vicenç Torrente-Segarra

  2. Rheumatology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain

    Manuel Fernandez Prada

  3. Rheumatology Department, Hospital Comarcal Laredo, Laredo, Spain

    Rosa Expósito Moliner

  4. Rheumatology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain

    Noemí Patricia Garrido Puñal

  5. Rheumatology Department, Complejo Hospital Universitario Lucus Augusti, Lugo, Spain

    Amalia Sánchez-Andrade Fernández

  6. Rheumatology Department, Hospital Universitario de Henares, Alcalá de Henares, Spain

    José Ramón Lamua Riazuelo

  7. Rheumatology Department, Hospital Germans Tries i Pujol, Badalona, Spain

    Alejandro Olivé

  8. Rheumatology Department, Hospital General Universitario de Elche, Elche, Spain

    Juan Víctor Tovar Beltrán

Authors
  1. Vicenç Torrente-Segarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manuel Fernandez Prada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rosa Expósito Moliner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Noemí Patricia Garrido Puñal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amalia Sánchez-Andrade Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. José Ramón Lamua Riazuelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alejandro Olivé
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Juan Víctor Tovar Beltrán
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

RENACER Study Group (REgistro NAcional CERtolizumab)

  • José Antonio González Ferrández
  • , Carmen Moragues Pastor
  • , Ana Urruticoechea Arana
  • , José Rey Rey
  • , Raúl Veiga Cabello
  • , Ángel Aragón Díez
  • , Noelia Vázquez Fuentes
  • , Anna Martínez Cristóbal
  • , Mª del Pilar Navarro Alonso
  • , Sergi Ordoñez Palau
  • , Alejandro Muñoz Jiménez
  • , José Miguel Ruiz Martín
  • , Asuncion Acosta Pereira
  • , Ángel María García Aparicio
  • , Jesús Carlos Fernández
  • , Mercedes Morcillo
  • , Emilio Giner Serret
  • , Nuria Montala Palau
  • , Carlos Rodríguez Escalera
  • , José Campos Esteban
  • , Juan José de Agustín de Oro
  • , Pedro Giralt Celiméndiz
  • , Desireé Ruiz Vílchez
  • , Silvia Paredes González-Albo
  • , Laura Garrido Courel
  • , Carmen Olga Sánchez González
  • , Maria del Pilar Ahijado Guzmán
  • , Patricia Castro Pérez
  • , Rosa Garcia Portales
  • , Julia Fernández Melón
  • , Gabriel Mercadal Orfila
  • , José Raúl Noguera Pons
  • , Concepción Moll Tuduri
  • , Mª Dolores García Armario
  • , Víctor Eliseo Quevedo Vila
  • , Juan José Lerma Garrido
  • , Antonio Gracia Pérez
  • , Elena Aurrecoechea Aguinaga
  • , Amalia Rueda Cid
  • , Marina Soledad Moreno García
  • , Eduardo Loza Cortina
  • , Delia Taverner Torrent
  • , Rebeca Belmonte Gómez
  • , María Jesús Martínez Blasco
  • , Raúl Moreno Domínguez
  • , Jenaro Graña Gil
  • , Raúl Cortés Verdú
  • , Mª Teresa Ruiz Jimeno
  • , Cristina Mata Arnaiz
  • , Georgina Salvador Alarcón
  • , Ana María Fernández Ortiz
  • , Marco Moreno Zazo
  • , Susana Barona Trapote
  • , Manuel Utrilla Utrilla
  • , Jaime Calvo Alén
  • , César Antonio Egües Dubuc
  • , Azucena Hernández Sanz
  • , Mar López-Sidro Ibáñez
  • , César Díaz Torne
  • , Vicente Aldasoro Cáceres
  • , Vera Ortiz Santamaría
  • , Mª Ángeles Hernández del Río
  • , Leticia del Olmo Pérez
  • , Jesús Quijada Carrera
  • , Claudia Stoye
  • , Mª de los Ángeles Belmonte
  • , Mª Ángeles Acosta Mérida
  • , Carlos Tomás Roura
  • , Arantxa Conesa Mateos
  • , Joan Dalmau Carolà
  •  & José María Salazar Vallinas

Corresponding author

Correspondence to Vicenç Torrente-Segarra.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study has been approved by the relevant local ethics committee (Internal Code 13/34) of the Hospital General Hospitalet-Moisès Broggi (Hospitalet Llobregat, Spain).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

The members of the RENACER Study Group (REgistro NAcional CERtolizumab) were listed in the Acknowledgements section.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 50 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Torrente-Segarra, V., Fernandez Prada, M., Expósito Moliner, R. et al. How elderly rheumatoid arthritis patients respond at one year of treatment with certolizumab pegol. Rheumatol Int 39, 395–398 (2019). https://doi.org/10.1007/s00296-018-4205-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-018-4205-z

Keywords

Search

Navigation